The company is broken down into three business lines: Next-Generation Sequencing or NGS, Biopharma, and Synthetic Biology. End users for these products include the industrial, agriculture, and medical sectors. Among the products Twist offers are synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. This somewhat unique life sciences concern is based out of South San Francisco. Therefore, we are going to circle back on Twist Bioscience today. The company has posted a couple of quarterly reports since then, and last week the stock saw an insider purchase. That turned out to be the right call, as TWST stock has dropped just over 60% since our first take on the firm. We should get a new set of data points to analyze, it should be noted, as third-quarter results will be out shortly." However, until management at Twist Biosciences shows significant strides lowering its quarterly cash burn rate and is much closer to getting to break-even status I will be avoiding the shares. We concluded that article back in November with the following conclusion:
It has been more than a half a year since our first look at Twist Bioscience Corporation ( NASDAQ: TWST ). "In late 2016 we expanded our manufacturing operations, and now, in addition to supporting Ginkgo's exponential growth, we are supplying DNA to accelerate research across multiple industries including pharmaceutical and biotechnology discovery, agricultural biotech and digital data storage.There are not nearly as many facts as there are opinions about the facts.”― Craig D. "We have increased our production capacity in parallel with our ability to manufacture longer genes more affordably, and today, with unmatched scale and pricing, we are shipping industry-leading volumes of DNA to customers around the world," said Emily Leproust, CEO of Twist Bioscience. "With the availability of synthetic genes up to 3.2kB from Twist, we are able to expedite the rapid prototyping of organism designs to generate cosmetics, nutritional ingredients, flavors, fragrances and other important ingredients." "Twist Bioscience continues to deliver record volumes of the highest-quality DNA to advance our organism engineering efforts, meeting or exceeding our aggressive timelines," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. Another contract was made between the two companies to continue the agreement into June 2016 for another 300 million base pairs through 2017. The agreement will equal to about 10% of the total DNA synthesis market in 2015. The partnership between the two companies will facilitate the production of functional/active ingredients for flavors, fragrances and cosmetics. In November 2015, the two companies came to an agreement that Twist Bioscience would deliver a minimum of 100 million base pairs of synthetic DNA to Ginkgo Bioworks throughout 2016. Synthetic DNA-manufacturer, Twist Bioscience is now shipping up to 3,200 base pairs of synthetic DNA (3.2 kilobase) in length to Ginkgo Bioworks under a previously agreed upon supplying agreement.
0 kommentar(er)
